Skin Cancer
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Sponsor: Krystal Biotech, Inc
Summary:
KB707-01 is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy. In this study, patients will receive KB707 via direct intratumoral (IT) injection into solid tumors to assess the safety and tolerability as well preliminary efficacy of KB707 monotherapy treatment. (summary from Clinicaltrials.gov)
Keywords: skin cancer, basal cell, squamous cell, melanoma, KB707
Age: 18 years or older
Location: Rancho Santa Mrgarita, CA
More information: Clinicaltrials.gov
Outcomes of Cutaneous Melanoma Patients Clinically Tested with DecisionDx®-Melanoma: A Prospective Registry (CONNECTION PRO)
Sponsor: Castle Biosciences
Summary: Please contact us for more information on this study.
Keywords: skin cancer, melanoma, Connection Pro, DecisionDX
Age: 18 years or older
Location: Rancho Santa Mrgarita, CA
Further Information: Contact our team for more information
DecisionDx-Melanoma Impact in Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes
Sponsor: Castle Biosciences
Summary: Please contact us for more information on this study.
Keywords: skin cancer, melanoma, DecisionDX, Lymph node, Biopsy, 31-GEP test
Age: 18 years or older
Further Information: Castle Biosciences
Location: Rancho Santa Mrgarita, CA